Monoclonal canine CD20 antibodies and methods of use
US9790280B2 · kind B2 · utility
10Cited by
12References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 25, 2012 |
| Grant date | Oct 17, 2017 |
| Priority date | — |
| Expiry date | Aug 28, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure relates to immunogens and monoclonal antibodies useful in the identification and/or treatment of cancer cells, including those of the dog. In one example, chimeric anti-canine CD20 antibodies are provided. The antibodies can be used therapeutically to treat lymphoma in dogs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.